Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 26.98% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 26.98% YoY), while the FY2025 annual figure was $2.0 billion, up 28.47% from the prior year.
• Other Non-Current Liabilities was $2.1 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $2.0 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $2.1 billion in Q1 2026 to a low of $43.7 million in Q3 2023.
• Historically, Other Non-Current Liabilities has averaged $1.2 billion across 5 years, with a median of $908.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 92.7% in 2023, then jumped 3432.27% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $638.0 million in 2022, then jumped by 33.87% to $854.1 million in 2023, then jumped by 83.98% to $1.6 billion in 2024, then gained by 28.47% to $2.0 billion in 2025, then gained by 5.32% to $2.1 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.